MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

The global urinary antibacterial and antiseptic pharmaceuticals market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 4.3% during the forecast period, driven by increasing ...

Over the next five years, we forecast operating profit margin to expand approximately 500 basis points, from 12.6% in 2023 to high double digits, which we think can be achieved with a combination of ...